Clinical Trial Update: A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase 1/2 study of ALKS 4230 (nemvaleukin alfa) in subjects with advanced solid tumors, with the trial completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ALKS 4230 (Nemvaleukin alfa) (Nemvaleukin alfa)

Snippet

Sponsor: Mural Oncology, Inc | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-05-21